Lipum advances to phase II with capital raise, moves production to...
On leap day, Lipum published the year-end report for 2023, where CEO Ola Sandborgh describes the progress as a "flying start to an exciting...
Chordate’s CEO presented at Swiss Nordic Bio
On March 7, Swiss Nordic Bio convened for its annual partnering and investor conference, facilitating connections between Nordic and Swiss life science companies, investors,...
Cereno’s new CMO and Head of R&D comments on progress with...
Cereno Scientific’s cardiovascular disease drug candidate CS1 has shown potential for clinical benefit both in preclinical studies as well as in the ongoing phase...
Rights issue to give Biosergen first in-human efficacy data
Recently having closed a partnership deal with Alkem, Biosergen is advancing its antifungal drug candidate BSG005 through clinical studies. With Alkem later financing phase...
BioInvent’s CEO comments on the study success in China
BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer...
Biosergen attacks invisible threat of fungal infections
How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they...
Elicera collaborates with US cancer centre to evaluate iTANK
Elicera Therapeutics is the sole biotech in Sweden developing CAR T-cell therapies. Beyond that, the company has developed a technology - the iTANK platform...
Biosergen CEO: “Positive data give us a strong value proposition”
Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug candidate BSG005....
Neola initiates usability study ahead of FDA approval
Lund-based Neola Medical continues to advance towards clinical studies with its lung monitoring system. The company is now starting a usability study - an...
Cyxone’s CEO gives a status update
Cyxone recently reached a milestone in its rheumatoid arthritis project, rabeximod, when succeeding in identifying the molecule's target protein. This means that it is...